[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370699-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370699-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","precision-immune-regulation-in-kras-mutated-cancers-the-final-piece-of-the-puzzle","Precision immune regulation in KRAS-mutated cancers - the final piece of the puzzle","","Targeted therapies for KRAS-mutated tumors have advanced rapidly, making the earlier view of KRAS as “undruggable” outdated. Yet KRAS mutation-targeted treatment remains constrained by resistance, efficacy limitations, toxicity concerns, and obstacles in drug development. KRAS mutations also remodel the immune microenvironment, creating both challenges and actionable opportunities for immunotherapy. This review traces KRAS-targeted therapy history, summarizes immune microenvironment changes and potential therapeutic targets, and compares differences across mutation types and co-mutation subtypes while outlining future research directions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/precision-immune-regulation-in-kras-mutated-cancers-the-final-piece-of-the-puzzle/370699/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/precision-immune-regulation-in-kras-mutated-cancers-the-final-piece-of-the-puzzle/370699.png","ImageObject",300,407,{"name":42,"@type":43},"Nguyễn Văn Học","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are KRAS mutations still challenging targets for therapy?","Question",{"text":63,"@type":64},"Despite rapid progress, KRAS mutation-targeted treatments face resistance, efficacy concerns, toxicity issues, and difficulties in developing drugs that work broadly across KRAS mutation variants.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do KRAS mutations influence the tumor immune microenvironment?",{"text":68,"@type":64},"KRAS mutations shape the immune microenvironment, which affects tumor progression and the effectiveness of treatments, including immunotherapy approaches like immune checkpoint inhibition.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review compare regarding KRAS-mutated cancers?",{"text":72,"@type":64},"The review compares immune microenvironment differences across various KRAS mutation types and co-mutation subtypes, explaining how these variations can alter immunotherapy choices and outcomes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370699,1790715094,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Fu etal. Journal of Experimental & Clinical Cancer Research (2025) 44:189 [https://doi.org/10.1186/s13046-025-03444-1](https://doi.org/10.1186/s13046-025-03444-1)  \nJournal of Experimental & Clinical Cancer Research  \nREVIEW Open Access  \nPrecision immune regulation in KRAS-mutated  cancers: the final piece of the puzzle?  \nShenao Fu 1†, Jiayao Ma 1†, Changjing Cai 1, Jun Tan3, Xiangying Deng 1,2, Hong Shen 1,2, Shan Zeng 1,2*, Yihong Chen 1* andYing Han 1*  \nAbstract  \nIn recent years, the development of targeted therapies for tumors with KRAS mutations has progressed rapidly, rendering the notion of KRAS as “undruggable” outdated. However, targeted therapies for KRAS mutations still face numerous challenges, including resistance, efficacy concerns, toxicity issues, and hurdles in drug development. Exploring alternative treatment modalities is thus essential. Extensive research has demonstrated that KRAS mutations significantly influence the immune microenvironment, presenting both challenges and opportunities for immunotherapy. Interestingly, it has been observed that different KRAS mutations and co-mutation subtypes exhibit significant variations in their immunological microenvironments, which undoubtedly impact immunotherapy choices. Here, we review the history of KRAS-targeted therapy, highlighting existing challenges, and summarize changes in the immune microenvironment of KRAS-mutated cancers and their potential therapeutic targets. We compare differences in the immune microenvironment across various mutation types and co-mutation subtypes, and offer perspectives on future research directions.  \nKeywords KRAS, Cancer, Targeted therapy, Immunotherapy, Microenvironment  \n†Shenao Fu, Jiayao Ma equal contributors and co-first authors.  \n*Correspondence:  \nShan Zeng [zengshan2000@csu.edu.cn](zengshan2000@csu.edu.cn)[ ](zengshan2000@csu.edu.cn)Yihong Chen [208102142@csu.edu.cn](208102142@csu.edu.cn)[ ](208102142@csu.edu.cn)Ying Han [yinghan@csu.edu.cn](yinghan@csu.edu.cn)  \n1Department of Oncology, Xiangya Hospital, Central South University, Changsha, China  \n2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China  \n3Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China  \nIntroduction  \nKRAS is one of the most classical, significant, and highfrequency oncogenes, causing about one million deaths annually worldwide [1]. Structurally, it has the secondhighest mutation rate in human tumors, ranking first in pancreatic cancer and colon adenocarcinoma, after TP53, a major tumor suppressor gene. KRAS codon G12 is the most frequently mutated site in human tumors, accounting for approximately 90% of KRAS mutations and 12% of all cancer patients [2]. Functionally, wildtype KRAS binds GTP, activating downstream signaling pathways, while binding to GDP shuts down these signals. Because wild KRAS proteins have GTP-hydrolysis activity, activation of related pathways is temporary and controllable. Oncogenic mutations cripple KRAS GTPase activity, locking it in a GTP-bound state. This fuels the persistent activation of critical downstream pathways such as MAPK-ERK and PI3K/AKT, driving aggressive  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directl","cbCaiuI10ogGw5Vw","https://ap.wps.com/l/cbCaiuI10ogGw5Vw","pdf",3393435,31,"English","# Abstract\n# Introduction","[{\"question\":\"Why are KRAS mutations still challenging targets for therapy?\",\"answer\":\"Despite rapid progress, KRAS mutation-targeted treatments face resistance, efficacy concerns, toxicity issues, and difficulties in developing drugs that work broadly across KRAS mutation variants.\"},{\"question\":\"How do KRAS mutations influence the tumor immune microenvironment?\",\"answer\":\"KRAS mutations shape the immune microenvironment, which affects tumor progression and the effectiveness of treatments, including immunotherapy approaches like immune checkpoint inhibition.\"},{\"question\":\"What does the review compare regarding KRAS-mutated cancers?\",\"answer\":\"The review compares immune microenvironment differences across various KRAS mutation types and co-mutation subtypes, explaining how these variations can alter immunotherapy choices and outcomes.\"}]","Precision immune regulation in KRAS-mutated cancers - the final piece of the puzzle | PDF",1790189924,78,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fec24b3680c782ba828dd188e13ea6f3.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9036a850093bd11c31d665a3338c9447.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c4fb0cf009799f500086f5cf56c2ea8.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42356b52d8eeb20f906a412b40339213.webp",980,1306]